Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory Securities Investigation

Abeona Therapeutics Securities Fraud Investigation

Analysis based on 13 articles · First reported Aug 27, 2026 · Last updated Sep 03, 2026

Sentiment
-30
Attention
2
Articles
13
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investigation and the underlying revenue recognition shortfall have negatively impacted Abeona's stock price, which fell nearly 15% on the disclosure. The ongoing investigation may lead to further volatility and potential legal liabilities for the company, affecting investor confidence in the near term.

Biotechnology Pharmaceuticals

Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (Nasdaq: ABEO) concerning potential securities fraud or other unlawful business practices by the company and certain officers and/or directors. The investigation follows Abeona's August 13, 2026 press release reporting Q2 2026 financial results and an update on commercial execution for ZEVASKYN (prademagene zamikeracel). Abeona disclosed that while five patients were treated with the one-time therapy, only four treatments were recognized for revenue, as one batch lacked the minimum number of sheets required for revenue recognition. Following this news, Abeona's stock price fell $1.12 per share, or 14.95%, to close at $6.35 per share on August 13, 2026. Pomerantz LLP, a prominent securities class action firm, is investigating whether Abeona and its management misled investors regarding the commercial performance of ZEVASKYN.

100 Abeona Therapeutics disclosed revenue shortfall
80 Pomerantz LLP launched investigation Abeona Therapeutics
stock
Abeona is the subject of the investigation. The company's stock dropped 14.95% after disclosing a revenue recognition shortfall for ZEVASKYN, and it now faces potential securities fraud claims.
Importance 100.0 Sentiment -40.0
priv
Pomerantz LLP is the law firm conducting the investigation. It is acting on behalf of investors and its actions could lead to litigation against Abeona.
Importance 80.0 Sentiment 0.0
exch
Nasdaq is the exchange where Abeona's stock is listed. The event affects the trading of ABEO shares but has no direct impact on the exchange itself.
Importance 10.0 Sentiment 0.0
Pomerantz LLP related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.